These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 12436336)

  • 1. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice.
    Alberts P; Engblom L; Edling N; Forsgren M; Klingström G; Larsson C; Rönquist-Nii Y; Ohman B; Abrahmsén L
    Diabetologia; 2002 Nov; 45(11):1528-32. PubMed ID: 12436336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
    Alberts P; Nilsson C; Selen G; Engblom LO; Edling NH; Norling S; Klingström G; Larsson C; Forsgren M; Ashkzari M; Nilsson CE; Fiedler M; Bergqvist E; Ohman B; Björkstrand E; Abrahmsen LB
    Endocrinology; 2003 Nov; 144(11):4755-62. PubMed ID: 12960099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
    Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity.
    Liu J; Wang L; Zhang A; Di W; Zhang X; Wu L; Yu J; Zha J; Lv S; Cheng P; Hu M; Li Y; Qi H; Ding G; Zhong Y
    Endocr J; 2011; 58(3):199-209. PubMed ID: 21325744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
    Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
    Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
    Taylor A; Irwin N; McKillop AM; Flatt PR; Gault VA
    Biol Chem; 2008 Apr; 389(4):441-5. PubMed ID: 18225986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
    Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
    Livingstone DE; Walker BR
    J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice.
    Yuan X; Li H; Bai H; Zhao X; Zhang C; Liu H; Zhang Y; Zhao B; Wu Y; Liu J; Xiang Q; Feng B; Chu Y; Huang Y
    Eur J Pharmacol; 2016 Oct; 788():140-151. PubMed ID: 27242185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
    Zhang X; Zhou Z; Yang H; Chen J; Feng Y; Du L; Leng Y; Shen J
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4455-8. PubMed ID: 19564108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
    Blum A; Favia AD; Maser E
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):132-6. PubMed ID: 18822345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of high-fat diet on KKAy and ob/ob mouse liver and adipose tissue corticosterone and 11-dehydrocorticosterone concentrations.
    Alberts P; Rönquist-Nii Y; Larsson C; Klingström G; Engblom L; Edling N; Lidell V; Berg I; Edlund PO; Ashkzari M; Sahaf N; Norling S; Berggren V; Bergdahl K; Forsgren M; Abrahmsén L
    Horm Metab Res; 2005 Jul; 37(7):402-7. PubMed ID: 16034710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
    Desbriere R; Vuaroqueaux V; Achard V; Boullu-Ciocca S; Labuhn M; Dutour A; Grino M
    Obesity (Silver Spring); 2006 May; 14(5):794-8. PubMed ID: 16855188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice.
    Wang L; Liu J; Zhang A; Cheng P; Zhang X; Lv S; Wu L; Yu J; Di W; Zha J; Kong X; Qi H; Zhong Y; Ding G
    PLoS One; 2012; 7(7):e40056. PubMed ID: 22768329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Attenuates High-Fat Diet-Induced Hepatic Steatosis in Mice.
    Li H; Sheng J; Wang J; Gao H; Yu J; Ding G; Ding N; He W; Zha J
    Drug Des Devel Ther; 2021; 15():2309-2324. PubMed ID: 34103895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
    Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
    Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.
    Barf T; Vallgårda J; Emond R; Häggström C; Kurz G; Nygren A; Larwood V; Mosialou E; Axelsson K; Olsson R; Engblom L; Edling N; Rönquist-Nii Y; Ohman B; Alberts P; Abrahmsén L
    J Med Chem; 2002 Aug; 45(18):3813-5. PubMed ID: 12190302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
    Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
    Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
    J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
    Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
    J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.